McDermott + Bull has successfully placed Hussain Rangwala as Chief Technology Officer at Inari Medical. Reporting to the CEO, Hussain will drive the development and execution of innovative R&D strategies, including fostering a culture of innovation, ensuring regulatory compliance, and overseeing quality assurance across all product development activities.
Hussain brings extensive experience from his tenure at MicroVention-Terumo, where he held multiple leadership roles including Chief Technology Officer and Global Vice President of Operations and R&D. His background in neurovascular product development, regulatory submissions, and manufacturing has positioned him as a leader in medical device innovation. Prior to MicroVention-Terumo, Hussain contributed to heart valve product development at Jena Valve and Medtronic Inc. He holds a Ph.D. in mechanical and aerospace engineering from the University at Buffalo.
Inari Medical, headquartered in Irvine, CA, is a commercial-stage medical device company focused on developing products to treat venous diseases. Inari’s innovative catheter-based mechanical thrombectomy systems are designed specifically for the venous system to treat deep vein thrombosis and pulmonary embolism. With a strong commitment to patient-focused product development, Inari is dedicated to transforming the treatment of venous diseases.
This executive search was completed by McDermott + Bull Co-Founder + Managing Partner Chris Bull, Partner Ken Dropiewski, Directors Anne Terry and Shelby Varon, and Research Associate Michael Matranga.